SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-07-23 |
| Reported value | $206,475,858 |
| Positions | 8 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| KESTRA MED TECHNOLOGIES LTD | KMTS | SHS | $69,417,594 | 2,728,679 |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $42,949,921 | 1,591,917 |
| AVALYN PHARMACEUTICALS INC | AVLN | COM SHS | $30,609,806 | 929,824 |
| AGOMAB THERAPEUTICS NV | AGMB | SPONSORED ADS | $19,972,352 | 1,538,702 |
| EVOMMUNE INC | EVMN | COM SHS | $18,499,547 | 1,391,990 |
| INVENTIVA SA | IVA | ADS | $13,733,424 | 3,633,181 |
| ABIVAX SA | ABVX | SPONSORED ADS | $10,410,938 | 78,125 |
| NYXOAH S A | NYXH | SHS | $882,276 | 522,057 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.